Continued treatment with AXS-05, a combination of dextromethorphan and bupropion, significantly reduces the risk for recurrence of Alzheimer’s disease–related agitation, phase 3 results show.

Axsome Therapeutics, Inc.’s AXSM share price has dipped by 8.23%, which has investors questioning if this is right time to ...